Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk Inc. has won an adverse jury instruction sanction against Washington state for its failure to preserve evidence in a False Claims Act case against the pharmaceutical company.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy ...